Freshfields advised AstraZeneca on its $2 billion strategic equity investment and clinical collaboration with Summit Therapeutics

Freshfields advised AstraZeneca on its $2 billion strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer. Learn more about the transaction here.

The Freshfields team was led by M&A partner Oliver Board and senior associate Ryan Taylor, and included partners Julian Long and Jennifer Bethlehem, associate Richard Bae Gong and trainee associate Fraser Hay. Partners Kristen Riemenschneider and Andrea Devoe, senior associate Jake Silvers and associates Rhea Khakhria and Shannon O’Hara advised on life sciences matters; partners Jenny Leahy, Mary Lehner, Dominic Divivier and Simon Priddis, senior associate Justin Chen and principal associate Niklas Andree advised on competition matters; partner Michael Levitt and associates Kevin Meehan and Kelli Nguyen advised on capital markets matters; and partner Jeffrey Gould advised on convertible equity matters.